scholarly journals Temporal Effects of Combined Birinapant and Paclitaxel on Pancreatic Cancer Cells Investigated via Large-Scale, Ion-Current-Based Quantitative Proteomics (IonStar)

2018 ◽  
Vol 17 (4) ◽  
pp. 655-671 ◽  
Author(s):  
Xue Wang ◽  
Jin Niu ◽  
Jun Li ◽  
Xiaomeng Shen ◽  
Shichen Shen ◽  
...  
2017 ◽  
Vol 89 (2) ◽  
pp. 1138-1146 ◽  
Author(s):  
Ling Hao ◽  
Jillian Johnson ◽  
Christopher B. Lietz ◽  
Amanda Buchberger ◽  
Dustin Frost ◽  
...  

2021 ◽  
Author(s):  
Maria Kalli ◽  
Ruxuan Li ◽  
Gordon B Mills ◽  
Triantafyllos Stylianopoulos ◽  
Ioannis K Zervantonakis

New treatments for patients with advanced or metastatic pancreatic cancers are urgently needed due to their resistance to all current therapies. Current studies focus on alternative treatment approaches that target or normalize the abnormal microenvironment of pancreatic tumors, which among others, is responsible for elevated mechanical stress in the tumor interior. Nevertheless, the underlying mechanisms by which mechanical stress regulates pancreatic cancer metastatic potential remain elusive. Herein, we used a large-scale proteomic assay to profile mechanical stress-induced signaling cascades that drive the motility of pancreatic cancer cells. Proteomic analysis, together with selective protein inhibition and siRNA treatments, revealed that mechanical stress enhances cell migration through activation of the p38 MAPK/HSP27 and JNK/c-Jun signaling axes, and activation of the actin cytoskeleton remodelers: Rac1, cdc42, and Myosin II. Our results highlight targeting aberrant signaling in cancer cells that are adapted to the mechanical tumor microenvironment as a novel approach to effectively limit pancreatic cancer cell migration.


2014 ◽  
Author(s):  
Chandra K. Singh ◽  
Satwinderjeet Kaur ◽  
Jasmine George ◽  
Molly C. Pellitteri-Hahn ◽  
Cameron O. Scarlett ◽  
...  

Oncotarget ◽  
2015 ◽  
Vol 6 (12) ◽  
pp. 10335-10349 ◽  
Author(s):  
Chandra K. Singh ◽  
Satwinderjeet Kaur ◽  
Jasmine George ◽  
Minakshi Nihal ◽  
Molly C. Pellitteri Hahn ◽  
...  

2020 ◽  
Author(s):  
Young Eun Kim ◽  
Eun-Kyung Kim ◽  
Min-Jeong Song ◽  
Tae-Young Kim ◽  
Ho Hee Jang ◽  
...  

AbstractOxaliplatin is a commonly used chemotherapeutic drug for the treatment of pancreatic cancer. Understanding the cellular mechanisms of oxaliplatin resistance is important for developing new strategies to overcome drug resistance in pancreatic cancer. In this study, we performed a stable isotope labelling by amino acids in cell culture (SILAC)-based quantitative proteomic analysis of oxaliplatin-resistant and sensitive pancreatic cancer PANC-1 cells. We identified 107 proteins whose expression levels changed between oxaliplatin-resistant and sensitive cells, which were involved in multiple biological processes, including DNA repair, drug response, apoptotic signalling, and the type 1 interferon signalling pathway. Notably, myristoylated alanine-rich C-kinase substrate (MARCKS) and wntless homolog protein (WLS) were upregulated in oxaliplatin-resistant cells compared to sensitive cells, as confirmed by qRT-PCR and Western blot analysis. We further demonstrated the activation of AKT and β-catenin signalling (downstream targets of MARCKS and WLS, respectively) in oxaliplatin-resistant PANC-1 cells. Additionally, we show that the siRNA-mediated suppression of both MARCKS and WLS enhanced oxaliplatin sensitivity in oxaliplatin-resistant PANC-1 cells. Taken together, our results provide insights into multiple mechanisms of oxaliplatin resistance in pancreatic cancer cells and reveal that MARCKS and WLS might be involved in the chemotherapeutic resistance in pancreatic cancer.


2009 ◽  
Vol 81 (2) ◽  
pp. 764-771 ◽  
Author(s):  
Yingchun Zhao ◽  
Wai-Nang Paul Lee ◽  
Shu Lim ◽  
Vay Liang Go ◽  
Jing Xiao ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document